Page last updated: 2024-10-30

loratadine and Asthma, Bronchial

loratadine has been researched along with Asthma, Bronchial in 47 studies

Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.
loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.

Research Excerpts

ExcerptRelevanceReference
"Loratadine added to montelukast has been suggested to improve endpoints of asthma."9.14A randomized study comparing the effect of loratadine added to montelukast with montelukast, loratadine, and beclomethasone monotherapies in patients with chronic asthma. ( Dass, SB; Liu, N; Lu, S; Reiss, TF, 2009)
"Ten adults with mild-to-moderate atopic asthma participated in a randomized, 4-way crossover study design comparing placebo, 5 mg of desloratadine, 10 mg of montelukast, and the combination administered at 26 hours and 2 hours before each allergen challenge conducted at least 7 days apart."9.11Effect of combined montelukast and desloratadine on the early asthmatic response to inhaled allergen. ( Cockcroft, DW; Davis, BE; Todd, DC, 2005)
" In this study we investigated the effect of treatment with desloratadine (DL) on systemic inflammation and on nasal and bronchial mucosal inflammation after nasal allergen provocation (NP) in subjects with grass-pollen-allergic rhinitis and asthma."9.11Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients. ( Braunstahl, GJ; Fokkens, WJ; Hoogsteden, HC; Kleinjan, A; Overbeek, SE; Reinartz, SM; van Drunen, CM, 2005)
"Asthma symptoms and beta(2)-agonist were improved significantly in patients with concomitant SAR and asthma treated with desloratadine 5 mg as well as montelukast 10 mg once daily."9.10Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. ( Baena-Cagnani, CE; Berger, WE; Danzig, M; DuBuske, LM; Gurné, SE; Lorber, R; Stryszak, P, 2003)
"Loratadine has a mild bronchodilatory effect in the study period and does not interfere with the bronchodilatory effect of terbutaline in childhood asthma."9.10The bronchodilatory effects of loratadine, terbutaline, and both together versus placebo in childhood asthma. ( Baki, A; Orhan, F, 2003)
"This 4-week, multicenter, parallel-group, double-blind study evaluated desloratadine treatment (5 mg once daily) versus placebo in 331 subjects with SAR and mild seasonal allergic asthma."9.10Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. ( Berger, WE; Mansfield, LE; Schenkel, EJ, 2002)
"Montelukast sodium, a potent, oral, specific leukotriene-receptor antagonist, has demonstrated clinical efficacy in the treatment of chronic asthma."9.09Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. ( Finn, AF; Geissler, L; Nguyen, H; Peszek, I; Reicin, A; Seidenberg, BC; Weinstein, SF; White, R, 2000)
"We sought to determine the efficacy and safety of loratadine (5 mg) plus pseudoephedrine (120 mg) (L/P) twice daily in patients with seasonal allergic rhinitis and mild asthma."9.08Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. ( Aaronson, D; Beaucher, W; Berkowitz, R; Bronsky, E; Chen, R; Chervinsky, P; Cohen, R; Corren, J; Fourre, J; Grossman, J; Harris, AG; Meltzer, E; Pedinoff, A; Stricker, W; Wanderer, A, 1997)
"To evaluate whether loratadine, a selective H1 receptor antagonist, given as an adjunct to standard asthma medication would have any effect in patients with moderate-to-severe asthma."9.08Lack of effect of loratadine on moderate to severe asthma. ( Ekström, T; Osterman, K; Zetterström, O, 1995)
"The results of this study show that loratadine, employed as an adjuvant therapeutic agent for the treatment of allergic bronchial asthma has a positive effect on symptomatology."9.07[Allergic bronchial asthma treated with Loratadine]. ( Kroll, VM; Nothofer, B; Werdermann, K, 1993)
" In a randomized, double-blind, crossover study, we evaluated the effects of loratadine, 10 and 20 mg, and placebo administered once daily for 3 days on the skin-wheal responses to histamine, the airway responses to inhaled histamine and methacholine, and the skin-wheal and airway responses to allergen in 12 subjects with asthma."9.06Comparison of the effect of loratadine on the airway and skin responses to histamine, methacholine, and allergen in subjects with asthma. ( Holgate, ST; Town, GI, 1990)
"Seventeen patients with perennial asthma, stable on a moderate dose of inhaled steroid, participated in a crossover study comparing the clinical effect of a non-sedative, potent and highly selective H1 antagonist (loratadine 10 mg) with placebo."9.06Effect of a non-sedative antihistaminic (loratadine) in moderate asthma. A double-blind controlled clinical crossover-trial. ( Dirksen, A; Engel, T; Frølund, L; Heinig, JH; Svendsen, UG; Weeke, B, 1989)
"To evaluate the efficacy and safety of loratadine, a new generation of antihistaminics, in the treatment of childhood asthma."8.87[Evaluation of efficacy and safety of loratadine in the treatment of childhood asthma]. ( Abduhaer, A; Maimaiti, G; Xu, PR, 2011)
"We sought to evaluate the effect of DL on allergic-airway responses in mice after inhalation of the naturally occurring aeroallergen Aspergillus fumigatus (Af ) and to examine the effects of DL on specific immune responses to a defined protein antigen with the use of an ovalbumin (OVA) model of asthma."7.72Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma. ( Bryce, PJ; Geha, R; Oettgen, HC, 2003)
"Desloratadine is a once-daily, non-sedating, non-impairing, selective histamine H1-receptor antagonist."6.43Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. ( DuBuske, LM, 2005)
"Loratadine added to montelukast has been suggested to improve endpoints of asthma."5.14A randomized study comparing the effect of loratadine added to montelukast with montelukast, loratadine, and beclomethasone monotherapies in patients with chronic asthma. ( Dass, SB; Liu, N; Lu, S; Reiss, TF, 2009)
"Montelukast and desloratadine synergistically inhibit the allergen-induced early asthmatic response."5.14Single-dose desloratadine and montelukast and allergen-induced late airway responses. ( Boulet, LP; Cockcroft, DW; Davis, BE; Deschesnes, F; Gauvreau, GM; Illamperuma, C; O'Byrne, PM; Watson, RM, 2009)
"Ten adults with mild-to-moderate atopic asthma participated in a randomized, 4-way crossover study design comparing placebo, 5 mg of desloratadine, 10 mg of montelukast, and the combination administered at 26 hours and 2 hours before each allergen challenge conducted at least 7 days apart."5.11Effect of combined montelukast and desloratadine on the early asthmatic response to inhaled allergen. ( Cockcroft, DW; Davis, BE; Todd, DC, 2005)
" In this study we investigated the effect of treatment with desloratadine (DL) on systemic inflammation and on nasal and bronchial mucosal inflammation after nasal allergen provocation (NP) in subjects with grass-pollen-allergic rhinitis and asthma."5.11Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients. ( Braunstahl, GJ; Fokkens, WJ; Hoogsteden, HC; Kleinjan, A; Overbeek, SE; Reinartz, SM; van Drunen, CM, 2005)
"This 4-week, multicenter, parallel-group, double-blind study evaluated desloratadine treatment (5 mg once daily) versus placebo in 331 subjects with SAR and mild seasonal allergic asthma."5.10Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. ( Berger, WE; Mansfield, LE; Schenkel, EJ, 2002)
"Sixteen atopic patients with mild-to-moderate asthma of whom 10 were receiving inhaled corticosteroid therapy (all had positive results to house dust mite on skin prick testing) were randomized in a double-blind, placebo-controlled, cross-over fashion to receive single doses of 5 mg of desloratadine, 180 mg of fexofenadine hydrochloride (FEX), 5 mg of levocetirizine dihydrochloride (LEV), or placebo, with AMP challenge performed 12 hours after dosing."5.10Comparative in vivo bioactivity of modern H1-antihistamines on AMP challenge in atopic asthma. ( Bates, CE; Currie, GP; Lee, DK; Lipworth, BJ, 2003)
"Asthma symptoms and beta(2)-agonist were improved significantly in patients with concomitant SAR and asthma treated with desloratadine 5 mg as well as montelukast 10 mg once daily."5.10Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. ( Baena-Cagnani, CE; Berger, WE; Danzig, M; DuBuske, LM; Gurné, SE; Lorber, R; Stryszak, P, 2003)
"The aim of the study was to evaluate the protective effect of single-dose, combination treatment comprising montelukast (5 mg) and loratadine (10 mg), on exercise-induced bronchoconstriction in asthmatic children."5.10The combination of single-dose montelukast and loratadine on exercise-induced bronchospasm in children. ( Boner, AL; De Gasperi, W; Loiacono, A; Micciolo, R; Peroni, DG; Piacentini, GL; Pietrobelli, A; Sabbion, A, 2002)
"On the basis of low dose inhaled corticosteroid, orally administered Loratadine significantly improves the therapeutic efficacy of asthma in patients with allergic asthma and rhinitis."5.10[Effects of H1 blocker and inhaled corticosteroids on asthmatic patients with allergic rhinitis]. ( Cai, DM; He, WQ; Lin, H; Liu, HZ; Ran, PX; Xu, JM; Zheng, JP; Zhong, NS, 2003)
"Loratadine has a mild bronchodilatory effect in the study period and does not interfere with the bronchodilatory effect of terbutaline in childhood asthma."5.10The bronchodilatory effects of loratadine, terbutaline, and both together versus placebo in childhood asthma. ( Baki, A; Orhan, F, 2003)
"Montelukast sodium, a potent, oral, specific leukotriene-receptor antagonist, has demonstrated clinical efficacy in the treatment of chronic asthma."5.09Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. ( Finn, AF; Geissler, L; Nguyen, H; Peszek, I; Reicin, A; Seidenberg, BC; Weinstein, SF; White, R, 2000)
"To evaluate whether loratadine, a selective H1 receptor antagonist, given as an adjunct to standard asthma medication would have any effect in patients with moderate-to-severe asthma."5.08Lack of effect of loratadine on moderate to severe asthma. ( Ekström, T; Osterman, K; Zetterström, O, 1995)
"We sought to determine the efficacy and safety of loratadine (5 mg) plus pseudoephedrine (120 mg) (L/P) twice daily in patients with seasonal allergic rhinitis and mild asthma."5.08Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. ( Aaronson, D; Beaucher, W; Berkowitz, R; Bronsky, E; Chen, R; Chervinsky, P; Cohen, R; Corren, J; Fourre, J; Grossman, J; Harris, AG; Meltzer, E; Pedinoff, A; Stricker, W; Wanderer, A, 1997)
"Twenty-four adult asthmatic subjects were included in a parallel group study that compared the duration of effect of two antihistamines and a placebo on cutaneous and inhaled reactivity to histamine."5.07Duration of effect of loratadine and terfenadine administered once a day for one week on cutaneous and inhaled reactivity to histamine. ( Cartier, A; Ghezzo, H; L'Archevêque, J; Labrecque, M; Malo, JL; Trudeau, C, 1993)
"The results of this study show that loratadine, employed as an adjuvant therapeutic agent for the treatment of allergic bronchial asthma has a positive effect on symptomatology."5.07[Allergic bronchial asthma treated with Loratadine]. ( Kroll, VM; Nothofer, B; Werdermann, K, 1993)
" In a randomized, double-blind, crossover study, we evaluated the effects of loratadine, 10 and 20 mg, and placebo administered once daily for 3 days on the skin-wheal responses to histamine, the airway responses to inhaled histamine and methacholine, and the skin-wheal and airway responses to allergen in 12 subjects with asthma."5.06Comparison of the effect of loratadine on the airway and skin responses to histamine, methacholine, and allergen in subjects with asthma. ( Holgate, ST; Town, GI, 1990)
"Seventeen patients with perennial asthma, stable on a moderate dose of inhaled steroid, participated in a crossover study comparing the clinical effect of a non-sedative, potent and highly selective H1 antagonist (loratadine 10 mg) with placebo."5.06Effect of a non-sedative antihistaminic (loratadine) in moderate asthma. A double-blind controlled clinical crossover-trial. ( Dirksen, A; Engel, T; Frølund, L; Heinig, JH; Svendsen, UG; Weeke, B, 1989)
"To evaluate the efficacy and safety of loratadine, a new generation of antihistaminics, in the treatment of childhood asthma."4.87[Evaluation of efficacy and safety of loratadine in the treatment of childhood asthma]. ( Abduhaer, A; Maimaiti, G; Xu, PR, 2011)
"We sought to evaluate the effect of DL on allergic-airway responses in mice after inhalation of the naturally occurring aeroallergen Aspergillus fumigatus (Af ) and to examine the effects of DL on specific immune responses to a defined protein antigen with the use of an ovalbumin (OVA) model of asthma."3.72Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma. ( Bryce, PJ; Geha, R; Oettgen, HC, 2003)
"The influence of single and repeated LO (10 mg/day) doses on histamine-induced bronchoconstriction was studied in 11 patients with stabile bronchial asthma."3.68[Effect of loratadine (LO), a selective H1 antagonist, on histamine-induced bronchoconstriction]. ( Cieślewicz, G; Gondorowicz, K; Grzelewska-Rzymowska, I; Rozniecki, J; Wojciechowska, B, 1992)
"Montelukast was not significantly different from placebo."2.71Effects of mediator antagonism on mannitol and adenosine monophosphate challenges. ( Anderson, SD; Brannan, JD; Currie, GP; Fowler, SJ; Haggart, K; Lee, DK; Lipworth, BJ; Wilson, AM, 2003)
"Treatment with montelukast and loratadine inhibited the release of cysteinyl leukotrienes and histamine into the airways, but did not inhibit the release of columnar epithelial cells into the airways."2.71Inflammatory basis of exercise-induced bronchoconstriction. ( Aitken, ML; Hallstrand, TS; Henderson, WR; Moody, MW; Schwartz, LB; Wurfel, MM, 2005)
"Loratadine treatment was not more sedative than placebo and was not associated with cardiovascular events."2.71Prophylactic management of children at risk for recurrent upper respiratory infections: the Preventia I Study. ( Adam, D; Bismut, H; Bonini, S; Borres, MP; Canonica, GW; Canseco Gonzalez, C; Czarlewski, W; Danzig, MR; Grimfeld, A; Holgate, ST; Lobaton, P; Patel, P; Roman, I; Szczeklik, A, 2004)
"Desloratadine is a once-daily, non-sedating, non-impairing, selective histamine H1-receptor antagonist."2.43Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. ( DuBuske, LM, 2005)
"Triamcinolone is a commonly used synthetic corticosteroid that has recently been tested in a large clinical trial for chronic obstructive pulmonary disease and shown to have some benefits."2.41Triamcinolone: new and old indications. ( Doggrell, SA, 2001)
"Desloratadine is a new, selective, H(1)-receptor antagonist that also has anti-inflammatory activity."1.31Desloratadine: A new, nonsedating, oral antihistamine. ( Geha, RS; Meltzer, EO, 2001)
" The drug had no adverse cardiovascular effects in various animal models or when administered at 9 times the recommended adult dosage for 10 days in volunteers."1.31Desloratadine. ( Jarvis, B; McClellan, K, 2001)

Research

Studies (47)

TimeframeStudies, this research(%)All Research%
pre-19901 (2.13)18.7374
1990's13 (27.66)18.2507
2000's30 (63.83)29.6817
2010's3 (6.38)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, BE2
Illamperuma, C1
Gauvreau, GM1
Watson, RM1
O'Byrne, PM1
Deschesnes, F1
Boulet, LP1
Cockcroft, DW2
Ngamphaiboon, J1
Wirawarn, T1
Thongkaew, T1
Lu, S1
Liu, N1
Dass, SB1
Reiss, TF1
Wang, Y2
Wang, J1
Lin, Y2
Si-Ma, LF1
Wang, DH2
Chen, LG2
Liu, DK1
Maimaiti, G1
Abduhaer, A1
Xu, PR1
Sima, LF1
Li, L1
Peroni, DG1
Piacentini, GL1
Pietrobelli, A1
Loiacono, A1
De Gasperi, W1
Sabbion, A1
Micciolo, R1
Boner, AL1
Berger, WE2
Schenkel, EJ1
Mansfield, LE1
Bachert, C1
Lee, DK2
Bates, CE1
Currie, GP2
Lipworth, BJ2
Baena-Cagnani, CE2
DuBuske, LM2
Gurné, SE1
Stryszak, P1
Lorber, R1
Danzig, M1
Haggart, K1
Fowler, SJ1
Wilson, AM2
Brannan, JD1
Anderson, SD1
He, WQ1
Zheng, JP1
Ran, PX1
Liu, HZ1
Lin, H1
Cai, DM1
Xu, JM1
Zhong, NS1
Bryce, PJ1
Geha, R1
Oettgen, HC1
Orhan, F1
Baki, A1
Magnan, A1
Grimfeld, A1
Holgate, ST3
Canonica, GW1
Bonini, S1
Borres, MP1
Adam, D1
Canseco Gonzalez, C1
Lobaton, P1
Patel, P1
Szczeklik, A1
Danzig, MR1
Roman, I1
Bismut, H1
Czarlewski, W1
Hallstrand, TS1
Moody, MW1
Wurfel, MM1
Schwartz, LB1
Henderson, WR1
Aitken, ML1
Reinartz, SM1
Overbeek, SE1
Kleinjan, A1
van Drunen, CM1
Braunstahl, GJ1
Hoogsteden, HC1
Fokkens, WJ1
Todd, DC1
Kupczyk, M1
Bogacka, E1
Bocheńska-Marciniak, M1
Sterchaluk-Grzyb, E1
Tworek, D1
Kuna, P1
Siergiejko, Z1
Michalska, I1
Buko, Z1
Swiderska, M1
Chyrek-Borowska, S1
Ekström, T1
Osterman, K1
Zetterström, O1
Cieślewicz, G3
Gondorowicz, K3
Grzelewska-Rzymowska, I3
Rozniecki, J3
Labrecque, M1
Ghezzo, H1
L'Archevêque, J1
Trudeau, C1
Cartier, A1
Malo, JL1
Kroll, VM1
Nothofer, B1
Werdermann, K1
Roquet, A1
Dahlén, B1
Kumlin, M1
Ihre, E1
Anstrén, G1
Binks, S1
Dahlén, SE1
Corren, J1
Harris, AG1
Aaronson, D1
Beaucher, W1
Berkowitz, R1
Bronsky, E1
Chen, R1
Chervinsky, P1
Cohen, R1
Fourre, J1
Grossman, J1
Meltzer, E1
Pedinoff, A1
Stricker, W1
Wanderer, A1
Pospelova, RA1
Akimova, LG1
Kolganova, NA1
Zlatinskaia, GR1
Reicin, A1
White, R1
Weinstein, SF1
Finn, AF1
Nguyen, H1
Peszek, I1
Geissler, L1
Seidenberg, BC1
de Longueville, M1
Geha, RS1
Meltzer, EO1
McClellan, K1
Jarvis, B1
Papi, A1
Papadopoulos, NG1
Stanciu, LA1
Degitz, K1
Johnston, SL1
Doggrell, SA1
Wojciechowska, B2
Town, GI1
Dirksen, A1
Engel, T1
Frølund, L1
Heinig, JH1
Svendsen, UG1
Weeke, B1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Airway Responses to Montelukast and Desloratadine.[NCT00424580]12 participants Interventional2007-01-31Completed
The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis[NCT00119015]Phase 4102 participants (Actual)Interventional2005-07-31Terminated (stopped due to Difficulty in recruitment)
Validation Screening Protocol for the Diagnosis of Exercise-induced Bronchoconstriction in Young Elite Athletes (13-18 y)[NCT03587675]141 participants (Actual)Interventional2017-01-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Other Symptom Score Over 2 Week Randomized Treatment Period

"Patients recorded the severity of other symptoms, including itchy nose/eyes and post-nasal drip, twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The other symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks

Interventionunits on a scale (Median)
Fluticasone Propionate + Montelukast-0.24
Fluticasone Propionate + Placebo-0.14

Change From Baseline in Runny Nose Symptom Score Over 2 Week Randomized Treatment Period

"Patients recorded the severity of runny nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The runny nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks

Interventionunits on a scale (Median)
Fluticasone Propionate + Montelukast-0.52
Fluticasone Propionate + Placebo-0.29

Change From Baseline in Sneezing Symptom Score Over 2 Week Randomized Treatment Period

"Patients recorded the severity of sneezing twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The sneezing symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks

Interventionunits on a scale (Median)
Fluticasone Propionate + Montelukast-0.22
Fluticasone Propionate + Placebo-0.25

Change From Baseline in Stuffy Nose Symptom Score Over 2 Week Randomized Treatment Period

"Patients recorded the severity of stuffy nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The stuffy nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks

Interventionunits on a scale (Median)
Fluticasone Propionate + Montelukast-0.41
Fluticasone Propionate + Placebo-0.47

Change From Baseline in Total Nasal Symptom Score (TNSS) Over 2 Week Randomized Treatment Period

"Patients recorded the severity of sneezing, runny nose, stuffy nose, and other symptoms (itchy nose/eyes and post-nasal drip) twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The TNSS was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 24.~The baseline TNSS used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks

Interventionunits on a scale (Median)
Fluticasone Propionate + Montelukast-1.66
Fluticasone Propionate + Placebo-2.21

Reviews

8 reviews available for loratadine and Asthma, Bronchial

ArticleYear
[Evaluation of efficacy and safety of loratadine in the treatment of childhood asthma].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2011, Volume: 13, Issue:11

    Topics: Anti-Allergic Agents; Asthma; Forced Expiratory Volume; Humans; Loratadine; Peak Expiratory Flow Rat

2011
Therapeutic points of intervention and clinical implications: role of desloratadine.
    Allergy, 2002, Volume: 57 Suppl 75

    Topics: Asthma; Clinical Trials as Topic; Drug Administration Schedule; Histamine H1 Antagonists; Humans; Lo

2002
Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:14

    Topics: Adult; Aged; Animals; Anti-Inflammatory Agents; Asthma; Child; Child, Preschool; Chronic Disease; Cl

2005
[Airway hyperreactivity and respiratory allergy in children].
    Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993), 1996, Volume: 43 Spec No

    Topics: Allergens; Anti-Allergic Agents; Asthma; Bronchial Hyperreactivity; Chemotaxis, Leukocyte; Child; Ch

1996
What are the candidate groups for pharmacotherapeutic intervention to prevent asthma?
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2000, Volume: 11 Suppl 13

    Topics: Anti-Allergic Agents; Asthma; Cetirizine; Child; Clinical Trials as Topic; Cromolyn Sodium; Dermatit

2000
Desloratadine activity in concurrent seasonal allergic rhinitis and asthma.
    Allergy, 2001, Volume: 56 Suppl 65

    Topics: Asthma; Cholinergic Antagonists; Eosinophils; Histamine H1 Antagonists; Humans; Loratadine; Respirat

2001
Triamcinolone: new and old indications.
    Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:7

    Topics: Administration, Intranasal; Adult; Aerosols; Androstadienes; Anti-Inflammatory Agents; Arthritis, Rh

2001
Are antihistamines useful in managing asthma?
    Current opinion in allergy and clinical immunology, 2002, Volume: 2, Issue:1

    Topics: Acetates; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchospirometry; Cetirizine; Cyclopropa

2002

Trials

27 trials available for loratadine and Asthma, Bronchial

ArticleYear
Single-dose desloratadine and montelukast and allergen-induced late airway responses.
    The European respiratory journal, 2009, Volume: 33, Issue:6

    Topics: Acetates; Adult; Allergens; Analysis of Variance; Anti-Asthmatic Agents; Asthma; Bronchial Provocati

2009
Prevention of recurrent wheezing in young children by loratadine compared with ketotifen.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2009, Volume: 92, Issue:3

    Topics: Administration, Oral; Anti-Allergic Agents; Asthma; Child, Preschool; Double-Blind Method; Female; H

2009
A randomized study comparing the effect of loratadine added to montelukast with montelukast, loratadine, and beclomethasone monotherapies in patients with chronic asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2009, Volume: 46, Issue:5

    Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Asthma; Beclomethasone; Chronic Disease; Cr

2009
The combination of single-dose montelukast and loratadine on exercise-induced bronchospasm in children.
    The European respiratory journal, 2002, Volume: 20, Issue:1

    Topics: Acetates; Adolescent; Age Factors; Asthma; Asthma, Exercise-Induced; Child; Cross-Over Studies; Cycl

2002
Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2002, Volume: 89, Issue:5

    Topics: Adolescent; Adult; Aged; Asthma; Double-Blind Method; Drug Administration Schedule; Female; Histamin

2002
Comparative in vivo bioactivity of modern H1-antihistamines on AMP challenge in atopic asthma.
    The Journal of allergy and clinical immunology, 2003, Volume: 111, Issue:2

    Topics: Acetates; Adenosine Monophosphate; Adult; Aged; Asthma; Bronchial Provocation Tests; Cetirizine; Cro

2003
Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma.
    International archives of allergy and immunology, 2003, Volume: 130, Issue:4

    Topics: Acetates; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthm

2003
Effects of mediator antagonism on mannitol and adenosine monophosphate challenges.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2003, Volume: 33, Issue:6

    Topics: Acetates; Adenosine Monophosphate; Adult; Asthma; Bronchial Hyperreactivity; Bronchial Provocation T

2003
[Effects of H1 blocker and inhaled corticosteroids on asthmatic patients with allergic rhinitis].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2003, Volume: 26, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adult; Anti-Asthmatic Agents; Asthma; Beclomethasone; Child;

2003
The bronchodilatory effects of loratadine, terbutaline, and both together versus placebo in childhood asthma.
    Journal of investigational allergology & clinical immunology, 2003, Volume: 13, Issue:3

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Asthma; Bronchodilator Agents; Child;

2003
Prophylactic management of children at risk for recurrent upper respiratory infections: the Preventia I Study.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2004, Volume: 34, Issue:11

    Topics: Anti-Allergic Agents; Asthma; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Hist

2004
Inflammatory basis of exercise-induced bronchoconstriction.
    American journal of respiratory and critical care medicine, 2005, Sep-15, Volume: 172, Issue:6

    Topics: Acetates; Adolescent; Adult; Asthma; Bronchitis; Bronchoconstriction; Cross-Over Studies; Cyclopropa

2005
Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients.
    Allergy, 2005, Volume: 60, Issue:10

    Topics: Adult; Asthma; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Inflammation; Loratadine; Mal

2005
Effect of combined montelukast and desloratadine on the early asthmatic response to inhaled allergen.
    The Journal of allergy and clinical immunology, 2005, Volume: 116, Issue:4

    Topics: Acetates; Adult; Allergens; Anti-Asthmatic Agents; Asthma; Bronchial Provocation Tests; Cross-Over S

2005
[The effect of desloratadine on use of rescue beta2-agonists and symptoms in patients suffering from seasonal allergic rhinitis and asthma].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2005, Volume: 18, Issue:104

    Topics: Administration, Oral; Adult; Albuterol; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Broncho

2005
[The effect of loratadine on skin and bronchial reactivity and histamine liberation from basophils in patients with atopic asthma and allergic rhinitis].
    Pneumonologia i alergologia polska, 1994, Volume: 62, Issue:11-12

    Topics: Asthma; Basophils; Bronchial Provocation Tests; Histamine; Histamine Release; Humans; Loratadine; Rh

1994
Lack of effect of loratadine on moderate to severe asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1995, Volume: 75, Issue:3

    Topics: Adolescent; Adult; Aged; Asthma; Bronchodilator Agents; Chemotherapy, Adjuvant; Cross-Over Studies;

1995
[Effect of loratadine, selective antagonist of histamine H1 receptors, on histamine-induced bronchoconstriction].
    Pneumonologia i alergologia polska, 1995, Volume: 63, Issue:5-6

    Topics: Adult; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Drug Administration Schedule; Femal

1995
Duration of effect of loratadine and terfenadine administered once a day for one week on cutaneous and inhaled reactivity to histamine.
    Chest, 1993, Volume: 103, Issue:3

    Topics: Administration, Inhalation; Adult; Aged; Asthma; Bronchoconstriction; Dose-Response Relationship, Dr

1993
[Allergic bronchial asthma treated with Loratadine].
    Fortschritte der Medizin, 1993, Feb-20, Volume: 111, Issue:5

    Topics: Adult; Asthma; Bronchial Hyperreactivity; Female; Humans; Loratadine; Lung Volume Measurements; Male

1993
[Airway hyperreactivity and respiratory allergy in children].
    Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993), 1996, Volume: 43 Spec No

    Topics: Allergens; Anti-Allergic Agents; Asthma; Bronchial Hyperreactivity; Chemotaxis, Leukocyte; Child; Ch

1996
Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics.
    American journal of respiratory and critical care medicine, 1997, Volume: 155, Issue:6

    Topics: Adolescent; Adult; Airway Obstruction; Allergens; Anti-Asthmatic Agents; Asthma; Drug Therapy, Combi

1997
[Strategy for preventing upper respiratory tract infections. Consensus of the Consulting Committee].
    Allergie et immunologie, 1997, Volume: 29, Issue:3

    Topics: Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Asthma; Child, Pres

1997
Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma.
    The Journal of allergy and clinical immunology, 1997, Volume: 100, Issue:6 Pt 1

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Child; Double-Blind Method; Drug Therapy, Combination; E

1997
Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma.
    Archives of internal medicine, 2000, Sep-11, Volume: 160, Issue:16

    Topics: Acetates; Adolescent; Adult; Aged; Asthma; Chronic Disease; Cross-Over Studies; Cyclopropanes; Doubl

2000
Comparison of the effect of loratadine on the airway and skin responses to histamine, methacholine, and allergen in subjects with asthma.
    The Journal of allergy and clinical immunology, 1990, Volume: 86, Issue:6 Pt 1

    Topics: Adult; Allergens; Asthma; Bronchi; Bronchial Provocation Tests; Cyproheptadine; Female; Histamine; H

1990
Effect of a non-sedative antihistaminic (loratadine) in moderate asthma. A double-blind controlled clinical crossover-trial.
    Allergy, 1989, Volume: 44, Issue:8

    Topics: Adult; Asthma; Bronchi; Clinical Trials as Topic; Cyproheptadine; Double-Blind Method; Female; Force

1989

Other Studies

13 other studies available for loratadine and Asthma, Bronchial

ArticleYear
Synthesis and antihistamine evaluations of novel loratadine analogues.
    Bioorganic & medicinal chemistry letters, 2011, Aug-01, Volume: 21, Issue:15

    Topics: Animals; Anti-Allergic Agents; Asthma; Guinea Pigs; Histamine; Histamine Antagonists; Ileum; Loratad

2011
Design, synthesis and antihistamine evaluations of several N-hydroxyalkyl desloratadine analogues.
    Medicinal chemistry (Shariqah (United Arab Emirates)), 2012, Volume: 8, Issue:6

    Topics: Animals; Asthma; Chemistry Techniques, Synthetic; Drug Design; Female; Guinea Pigs; Histamine; Hista

2012
Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma.
    The Journal of allergy and clinical immunology, 2003, Volume: 112, Issue:1

    Topics: Allergens; Animals; Asthma; Bronchial Hyperreactivity; Cytokines; Disease Models, Animal; Dose-Respo

2003
[Respiratory allergies in the child and the adult].
    La Revue du praticien, 2004, Jan-31, Volume: 54, Issue:2

    Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Allergens; Anti-Allergic Ag

2004
[Combination therapy of allergic rhinitis. So that from hay fever asthma won't come].
    MMW Fortschritte der Medizin, 2004, May-27, Volume: 146, Issue:22

    Topics: Anti-Allergic Agents; Asthma; Child; Drug Therapy, Combination; Glucocorticoids; Histamine H1 Antago

2004
[Claritin in the combined therapy of bronchial asthma].
    Terapevticheskii arkhiv, 1997, Volume: 69, Issue:10

    Topics: Anti-Asthmatic Agents; Asthma; Drug Evaluation; Histamine H1 Antagonists; Humans; Loratadine; Remiss

1997
Desloratadine: A new, nonsedating, oral antihistamine.
    The Journal of allergy and clinical immunology, 2001, Volume: 107, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Drug Interactions; Histamine H1 Antagonist

2001
Desloratadine.
    Drugs, 2001, Volume: 61, Issue:6

    Topics: Asthma; Clinical Trials as Topic; Drug Interactions; Histamine H1 Antagonists; Humans; Loratadine; R

2001
Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells.
    The Journal of allergy and clinical immunology, 2001, Volume: 108, Issue:2

    Topics: Asthma; Bronchi; Epithelial Cells; HeLa Cells; Histamine H1 Antagonists; Humans; Intercellular Adhes

2001
[The third-generation antihistaminics. Can they prevent the tier change?].
    MMW Fortschritte der Medizin, 2002, Feb-14, Volume: 144, Issue:7

    Topics: Asthma; Bronchial Hyperreactivity; Histamine H1 Antagonists; Humans; Loratadine; Placebos; Randomize

2002
Desloratadine (Clarinex).
    The Medical letter on drugs and therapeutics, 2002, Mar-18, Volume: 44, Issue:1126

    Topics: Administration, Oral; Adolescent; Adult; Aged; Asthma; Controlled Clinical Trials as Topic; Disorder

2002
[Effect of loratadine--selective antagonist of histamine (H1) receptor--on allergen-induced bronchoconstriction in atopic asthmatics].
    Pneumonologia i alergologia polska, 1992, Volume: 60, Issue:11-12

    Topics: Adult; Animals; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Female; Humans; Humic Subs

1992
[Effect of loratadine (LO), a selective H1 antagonist, on histamine-induced bronchoconstriction].
    Pneumonologia i alergologia polska, 1992, Volume: 60, Issue:11-12

    Topics: Adult; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Female; Histamine; Humans; Loratadi

1992